The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
More than 10,000 scientific publications containing EUDRAGIT
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Acquisition of exclusive commercialization rights for European markets
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Launch of Indian public health standards for Ayush healthcare facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research
Subscribe To Our Newsletter & Stay Updated
